NCT06625190 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
| NCT ID | NCT06625190 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of Florida |
| Condition | Neuroblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 27 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 27 participants in total. It began in 2026-02-11 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be highly chemotherapy sensitive, many remain resistant and require multimodalities of treatment. Immunotherapy has been developed to harness the immune system in fighting solid tumors, though not all have targeted effects. Some solid tumors are treated with autologous transplants; however, they do not always demonstrate an improved event free survival or overall survival. There has been evidence of the use of allogeneic stem cell transplants to provide a graft versus tumor effect, though studies remain limited. By utilizing αβ-T cell and B cell depletion for stem cell transplants and combining with zoledronic acid, the immune system may potentially be harnessed and enhanced to provide an improved graft versus tumor effect in relapsed/refractory solid tumors and promote an improved event-free survival and overall survival. This study will investigate the safety of treatment with a stem cell graft depleted of αβ-T cell and CD19+ B cells in combination with zoledronic acid in pediatric and young adult patients with select solid tumors, as well as whether this treatment improves survival rates in these patients.
Eligibility Criteria
Inclusion Criteria: * Patients 6 months to ≤ 25 years old * Relapsed/Refractory Solid Tumor whom failed or deemed ineligible to receive autologous transplant or if autologous transplant did not offer \>20% chance of cure with the following diseases: 1. neuroblastoma (high risk with relapsed or refractory disease), 2. relapsed/refractory rhabdomyosarcoma, 3. relapsed/refractory non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): synovial sarcoma, malignant peripheral nerve sheath tumors (MPNST), 4. High risk adult type NRSTS: clear cell sarcoma, alveolar soft part sarcoma, 5. Other high-risk extracranial solid tumors: desmoplastic small round cell tumors, chordoma, malignant rhabdoid tumor, epithelioid sarcoma, myoepithelial tumor 6. relapsed/refractory bone tumors: osteosarcoma and Ewing sarcoma/PNET, or 7. Wilm's tumor or other high-risk solid tumors with \<10% expected survival with conventional treatment. * Subjects must not have more than one active malignancy at the time of enrollment. (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included.) * Haplo-identical related donor (at least one full haplotype must be matched). * Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients \>16 years of age and Lansky scores for patients ≤16 years of age * Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as: 1. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 50% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen. 2. Renal: Creatinine clearance or radioisotope GFR ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender 3. Cardiac: Ejection fraction of ≥ 40% by echocardiogram or radionuclide scan (MUGA). * Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures * Individuals of childbearing potential (IOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for one year following transplantation to minimize the risk of pregnancy. Prior to study enrollment, individuals of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factor for an unintentional pregnancy. * Subjects with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for one year following stem cell transplantation. Exclusion Criteria: * Patients with documented uncontrolled infection at the time of study entry are not eligible. a. Uncontrolled infection is patient without treatment antimicrobials and/or demonstrating progression despite antimicrobials * Patients with progressive solid tumor disease after relapsed/refractory treatment. * Demonstrated lack of compliance with medical care, as determined by the treating physician. * Patients who have received an allogeneic HSCT within 6 months. * Patients who do not have an eligible allogeneic donor available. * Patients with a life expectancy \<3 months * Patients not meeting inclusion criteria for organ function. * Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least one year after transplantation. * Females who are known to be pregnant or breastfeeding. * History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. * Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Contact & Investigator
Jordan Milner, MD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT06625190 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 25 Years, studying Neuroblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06625190 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06625190 currently recruiting?
Yes, NCT06625190 is actively recruiting participants. Contact the research team at mooregj@ufl.edu for enrollment information.
Where is the NCT06625190 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT06625190 clinical trial?
NCT06625190 is sponsored by University of Florida. The principal investigator is Jordan Milner, MD at University of Florida. The trial plans to enroll 27 participants.